Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $57.2 million.

  • Crinetics Pharmaceuticals' Net Cash Flow rose 27846.69% to $57.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.4 million, marking a year-over-year decrease of 21828.01%. This contributed to the annual value of $209.6 million for FY2024, which is 84334.05% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Net Cash Flow stood at $57.2 million for Q3 2025, which was up 27846.69% from -$40.8 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Net Cash Flow registered a high of $341.0 million during Q1 2024, and its lowest value of -$170.0 million during Q1 2025.
  • In the last 5 years, Crinetics Pharmaceuticals' Net Cash Flow had a median value of -$1.6 million in 2023 and averaged $979684.2.
  • Within the past 5 years, the most significant YoY rise in Crinetics Pharmaceuticals' Net Cash Flow was 390219.46% (2024), while the steepest drop was 561371.12% (2024).
  • Over the past 5 years, Crinetics Pharmaceuticals' Net Cash Flow (Quarter) stood at $39.2 million in 2021, then crashed by 95.5% to $1.8 million in 2022, then crashed by 5091.37% to -$87.9 million in 2023, then skyrocketed by 40.02% to -$52.7 million in 2024, then soared by 208.44% to $57.2 million in 2025.
  • Its last three reported values are $57.2 million in Q3 2025, -$40.8 million for Q2 2025, and -$170.0 million during Q1 2025.